Clinical trials for Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)

57 currently recruiting clinical trials
Phase 1 / Phase 2 Lymphoma CLL & Richter's syndrome Acute leukemia Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT07220616 #2025-522595-87-00
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
3 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05181735 #2021-000596-37
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo Secondary MDS
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
EPO / Growth factors
Required IPSS-R prognostic scores
Low Intermediate
Required IPSS-M prognostic scores
Low Moderately low
Excluded genetic anomalies
del(5q)
Excluded previous treatments
Systemic Treatment-Naive
28 recruiting sites
Groupe Francophone des Myélodysplasies
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05280509
Phase 2 Cohorte 1 Myélofibrose naïve au traitement par JAKi
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Targeted therapy
5 recruiting sites
Telios Pharma, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05280509
Phase 2 Cohorte 2 (réponse sous-optimale au ruxolitinib)
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Telios Pharma, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05601726
Syndromes myélodysplasiques
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo Secondary MDS
Required number of previous lines of therapy
1 2 3 or more
Required IPSS-R prognostic scores
High Very high
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Advanced BioDesign
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04176198 #2022-502597-16-00
Bras Nuvisertib (TP-3654) + Ruxolitinib
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Required M-IPSS70+ v2.0 scores
Intermediate High
Required MYSEC-PM scores
Intermediate-1 Intermediate-2 High
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04176198 #2022-502597-16-00
Bras Nuvisertib (TP-3654) + Momelotinib
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Required M-IPSS70+ v2.0 scores
Intermediate High
Required MYSEC-PM scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04176198 #2022-502597-16-00
Bras de monothérapie par nuvisertib
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Required M-IPSS70+ v2.0 scores
Intermediate High
Required MYSEC-PM scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT07469891 #2026-525484-40-00
Cohorte polyglobulie de Vaquez
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Polycythemia vera
Required genetic anomalies
JAK2
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
2 recruiting sites
Prelude Therapeutics Incorporated
Phase 1 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT07469891 #2026-525484-40-00
Cohorte Myélofibrose
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required genetic anomalies
JAK2
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
2 recruiting sites
Prelude Therapeutics Incorporated